ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0404

Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial

Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

1:00PM-3:00PM: Abstract Number: 0387

Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0327

SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0220

Social Media Use in Academic Rheumatology

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0332

Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0478

Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0350

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0353

Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0038

STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0108

Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0105

Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0385

T Cell Receptor Sequencing Identifies Two Classes of T Cells Enriched in HLA-B27-associated Inflammation

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0316

Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) – a Novel Treatment Approach for Rheumatoid Arthritis

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0271

Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0127

The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].